Research programme: zinc finger DNA binding protein transcription factors - Sangamo Therapeutics

Drug Profile

Research programme: zinc finger DNA binding protein transcription factors - Sangamo Therapeutics

Alternative Names: AAV-ZFP-VEGF; Ad-ZFP-VEGF; AdV-ZFP-VEGF; ZFP TF ATV; ZFP TF therapeutics - Sangamo

Latest Information Update: 29 May 2017

Price : $50

At a glance

  • Originator Sangamo BioSciences
  • Developer Sangamo BioSciences; Sangamo Therapeutics
  • Class Transcription factors; Zinc finger DNA binding proteins
  • Mechanism of Action Genetic transcription modulators; Glial cell line-derived neurotrophic factor agonists; Nav1.8 voltage-gated sodium channel inhibitors; Neuron stimulants; TrkA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Age-related macular degeneration; Alzheimer's disease; Cancer; Neuropathic pain; Parkinson's disease

Highest Development Phases

  • Preclinical Alzheimer's disease; Neuropathic pain; Parkinson's disease
  • Discontinued Age-related macular degeneration; Cancer

Most Recent Events

  • 15 May 2017 Minor update in pharmacodynamics data from preclinical studies in Alzheimer's disease released by Sangamo Therapeutics
  • 29 Mar 2017 Preclinical trials in Alzheimer's disease in USA (Parenteral)
  • 29 Mar 2017 Pharmacodynamics data from preclinical studies in Alzheimer's disease released by Sangamo Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top